COMP <GO>
RPRX vs MRK // DIVIDEND YIELD & FCF PAYOUT SAFETY
Royalty Pharma plc Class A Ordinary Shares (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: RPRX 7
— MRK 8
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: MRK
LAST: $67.18 (+1.90%) • MKT CAP: $37.91B
dividend-safety
0.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
dividend-safety
2.26%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RPRX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RPRX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.00% | 20.70% | -13.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 27.8x | 15.3x | +12.50 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 6.29% | 3.42% | +2.87 | RPRX | /fcf-yield <GO> |
| Operating Margin | 65.60% | 34.30% | +31.30 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 32.40% | 28.10% | +4.30 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) | 5.10% | 1.30% | +3.80 | RPRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.90 | 5.19 | -2.29 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | RPRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 76.7 | 56.9 | +19.87 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.92 | +0.02 | RPRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.8x | 18.4x | +27.40 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.91B | $361.02B | -$323.11B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RPRX REV | MRK REV | RPRX GROSS % | MRK GROSS % | RPRX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.38B | $65.01B | 44.0% | 74.8% | $2.38B | $12.36B |
| FY 2024 | $2.26B | $64.17B | 44.0% | 76.3% | $2.67B | $18.10B |
| FY 2023 | $2.35B | $60.12B | 44.0% | 44.0% | $2.88B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RPRX // BETA 0.94
MRK // BETA 0.92